US Reshoring Push Clouds Outlook for China Contract Drug Manufacturing Sector

China’s contract drug manufacturing industry is facing growing uncertainty as United States pharmaceutical companies accelerate efforts to bring production back onshore and restructure global supply chains. The shift reflects broader geopolitical tensions and strategic concerns around dependency on overseas manufacturing, particularly in critical

Chinese Drugmakers Hit Record US$136 Billion in Global Licensing Deals in 2025

Chinese pharmaceutical companies signed a record US$136 billion worth of out licensing agreements in 2025, underscoring the rapid rise of China as a major source of innovative drug development and reshaping the global biopharmaceutical landscape. According to industry analysts, the total value of